Watch KMTS. Know when insiders buy.
One email the day a filing lands. Free.
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
28.76
+0.44 +1.55%
USD · Oct 26, 08:40 a.m. ET
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
40
WATCH · insiders 25, shorts 54
Insiders, 90 days
−$3.8M
net selling · 0 buys, 10 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.7BP/E —DIV YIELD —FCF YIELD -7.17%REV TTM $106.7M +60.7%NET INCOME −$149.9MNET DEBT $3.9M52W 17.87 – 29.37NEXT EARNINGS Dec 14 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 2027 · Jul 31 | $31M | +59.9% | 56.5% | −$37.7M | −$44.1M | — | -0.75 | −$32.3M | $8.3M | −$40.6M | Sep 14 |
| Q4 2026 · Apr 30derived | $28.6M | +66.2% | 54.8% | −$39.3M | −$38.8M | — | -0.67 | −$18.7M | $9.7M | −$28.4M | Jul 14 |
| Q3 2026 · Jan 31 | $24.6M | +62.7% | 52.6% | −$34.8M | −$34.2M | — | -0.61 | −$18.4M | $9.8M | −$28.2M | Mar 17 |
| Q2 2026 · Oct 31 | $22.6M | +53.4% | 50.6% | −$31.8M | −$32.8M | — | -0.64 | −$18.3M | $7.3M | −$25.6M | Dec 11 |
| Q1 2026 · Jul 31 | $19.4M | +51.5% | 45.7% | −$28.9M | −$25.8M | — | -0.50 | −$26.3M | $8.2M | −$34.4M | Sep 14 |
| Q4 2025 · Apr 30derived | $17.2M | — | 44.3% | −$48.2M | −$52.1M | — | -1.57 | −$24.1M | $7.4M | −$31.4M | Jul 14 |
| Q3 2025 · Jan 31 | $15.1M | — | 43.4% | −$20.6M | −$21.5M | — | -1.25 | −$18M | $4.1M | −$22.1M | Mar 17 |
| Q2 2025 · Oct 31 | $14.7M | — | 39.6% | −$19.1M | −$20.4M | — | -1.19 | −$18.1M | $4.4M | −$22.5M | Dec 11 |
| Q1 2025 · Jul 31 | $12.8M | — | 32.9% | −$18.4M | −$19.9M | — | -1.12 | −$17.5M | $7M | −$24.5M | Sep 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2026 · to Apr 30 | $95.1M | 51.4% | −$134.7M | −$131.6M | -138.4% | -2.43 | −$81.7M | $34.9M | −$116.6M | — | — |
| FY2025 · to Apr 30 | $59.8M | 40.5% | −$106.4M | −$113.8M | -190.3% | -5.13 | −$77.6M | $22.9M | −$100.5M | — | — |
| FY2024 · to Apr 30 | $27.8M | 1.3% | −$85.1M | −$94.1M | -338.4% | -5.07 | −$72.2M | $12.2M | −$84.5M | — | — |
Every number comes from KESTRA MEDICAL TECHNOLOGIES, LTD.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.